The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
Open accessAbstract
OBJECTIVE: Early initiation of intensive diabetes therapy aimed at achieving near-normal glycemia reduces the early development of vascular complications in type 1 diabetes. We now assess whether intensive therapy compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the incidence of cardiovascular disease over 30 years of follow-up. RESEARCH DESIGN AND METHODS: The DCCT randomly assigned 1,441 patients with type 1 diabetes to intensive versus conventional therapy for a mean of 6.5 years, after which 93% were subsequently monitored during the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Cardiovascular disease (nonfatal myocardial infarction and stroke, cardiovascular death, confirmed angina, congestive heart failure, and coronary artery revascularization) was adjudicated using standardized measures. RESULTS: During 30 years of follow-up in DCCT and EDIC, 149 cardiovascular disease events occurred in 82 former intensive treatment group subjects versus 217 events in 102 former conventional treatment group subjects. Intensive therapy reduced the incidence of any cardiovascular disease by 30% (95% CI 7, 48; P = 0.016), and the incidence of major cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular death) by 32% (95% CI −3, 56; P = 0.07). The lower HbA1c levels during the DCCT/EDIC statistically account for all of the observed treatment effect on cardiovascular disease risk. Increased albuminuria was also independently associated with cardiovascular disease risk. CONCLUSIONS: Intensive diabetes therapy during the DCCT (6.5 years) has long-term beneficial effects on the incidence of cardiovascular disease in type 1 diabetes that persist for up to 30 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the post-DCCT follow-up of the EDIC cohort, participants previously randomized to the intensive treatment arm had a significant 57% reduction in the risk of the composite outcome of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death compared with those previously randomized to the standard treatment arm (58).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An HbA1c of 7.0% or greater puts people with diabetes at risk of developing macrovascular and microvascular complications, whereas a HbA1c less than 7.0% or reducing HbA1c by 1.0% prevents complications [5,6].”
From One drop | Mobile on iPhone and apple watch: an evaluation of hbA1c improvement associated with tracking self-care (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An HbA1c of 7.0% or greater puts people with diabetes at risk of developing macrovascular and microvascular complications, whereas a HbA1c less than 7.0% or reducing HbA1c by 1.0% prevents complications [5,6].”
From One drop | Mobile on iPhone and apple watch: an evaluation of hbA1c improvement associated with tracking self-care (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the DCCT cohort, there was a significant reduction in CV outcomes (42%), nonfatal myocardial infarct (MI), stroke and CV death (57%), as well as all-cause mortality (33%) in previously intensively treated participants compared with those who were previously in the standard arm (17)(18)(19).”
From Targets for Glycemic Control (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These benefits persisted beyond the end of the trial despite equivalent glucose levels in the two groups (HbA 1c 8% [64 mmol/mol]) in the posttrial period; furthermore, reductions in incident cardiovascular disease and mortality in the intensively treated group emerged with time (40).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [40]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“The landmark Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications studies have demonstrated that intensive insulin therapy reduces the risk of both micro-and macro-vascular complications in people with T1D.1,2”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, longer-term epidemiological follow-up of these studies also showed a pattern of CVD benefit (58-60).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“The importance of glycemic management was demonstrated convincingly by the DCCT (39) and the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study (40).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The glycemic control portion of the trial was prematurely terminated after 3.5 years due to higher mortality (1.41% vs. 1.14% per year, HR 1.22) associated with assignment to the intensive-treatment arm (19,20).”
From Targets for Glycemic Control (2018) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationThe Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Backlund, 2003, Validation of deaths and reported cardiovascular cerebrovascular events (Abstract). Control Clin Trials, 23
Cited by
Sorted by citations
Items 301–400 of 712
Sanchez, M., Kannengiesser, C., Hoang, S., Potier, L., Fumeron, F., Venteclef, N., Scheen, A. J., Gautier, J., Hadjadj, S., Marre, M., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01635-0 · Cited by 11
Holte, K. B., Svanteson, M., Hanssen, K. F., Sveen, K. A., Seljeflot, I., Solheim, S., Sell, D. R., Monnier, V. M., & Berg, T. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233174 · Cited by 11
Paliares, I. C., Dualib, P. M., Torres, L. S. N., Aroucha, P. M. T., de Almeida-Pititto, B., de Sá, J. R., & Dib, S. A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02460-3 · Cited by 14
Pemberton, J. S., Li, Z., Gal, R. L., Turner, L. V., Bergford, S., Calhoun, P. M., & Riddell, M. C. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111981 · Cited by 10
Nardone, M., Kugathasan, L., Sridhar, V. S., Dutta, P., Campbell, D. J. T., Layton, A. T., Perkins, B. A., Barbour, S. J., Lam, T. K. T., Levin, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000641 · Cited by 11
Syntaxin 17 Translocation Mediated Mitophagy Switching Drives Hyperglycemia‐Induced Vascular Injury
Luo, A., Wang, R., Gong, J., Wang, S., Yun, C., Chen, Z., Jiang, Y., Liu, X., Dai, H., Liu, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202414960 · Cited by 10
A primer on metabolic memory: why existing diabesity treatments fail
Çöpür, S., Rossing, P. R., Afşar, B., Sag, A. A., Siriopol, D. C., Kuwabara, M., Ortíz, A., & Kanbay, M. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa143 · Cited by 10
Pomposelli, T., Schuetz, C., Wang, P., & Yamada, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632605 · Cited by 11
Xu, M., Wu, X., Liu, Z., Ding, Y., Kong, W., Little, P. J., Xu, S., & Weng, J. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.07.031 · Cited by 10
Continuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 10
Corrales, P. J. P., Bellido, V., & Ampudia‐Blasco, F. J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.06.015 · Cited by 12
Epigenetics in the Development of Diabetic Cardiomyopathy
Pepin, M. E., & Wende, A. R. (2019) · Epigenomics · doi:10.2217/epi-2019-0027 · Cited by 10
Soulimane, S., Balkau, B., Vogtschmidt, Y. D., Toeller, M., Fuller, J., & Soedamah‐Muthu, S. S. (2022) · Diabetologia · doi:10.1007/s00125-022-05698-2 · Cited by 9
Cardiovascular safety of insulin: Between real‐world data and reality
Mannucci, E., & Ferrannini, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12967 · Cited by 10
McDonald, M. W., Dotzert, M. S., Jiang, M., Murray, M. R., Noble, E. G., & Melling, C. W. J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8485624 · Cited by 10
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
Hao, W., Jia, Y., Wang, C., & Wang, X. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109931 · Cited by 11
van den Heuvel, T. R. A., Kolassa, R., Keuthage, W., Kroeger, J., Ré, R., de Portu, S., Vorrink, L., Shin, J., Castañeda, J., Vigersky, R. A., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231161320 · Cited by 9
Eid, P., Creuzot-Garcher, C. P., Aho, S., Gabrielle, P., Charpin, E., Haddad, D., Steinberg, L.-A., Bron, A. M., Vergès, B. L., & Arnould, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072687 · Cited by 9
Metformin Impedes Oxidation of LDL In Vitro
Rossmann, C. R., Ranz, C., Kager, G., Ledinski, G., Köestenberger, M., Wonisch, W., Wagner, T., Schwaminger, S. P., Geronimo, B. D., Hrzenjak, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082111 · Cited by 9
Omar, N. N., El-Hefnawy, M. H., Soda, M. F. E., Heider, N. M., & Hamed, H. I. (2017) · Bulletin of Faculty of Pharmacy Cairo University · doi:10.1016/j.bfopcu.2017.05.002 · Cited by 9
Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 9
Kapelios, C. J., Bonou, M. S., Barmpagianni, A., Tentolouris, A., Tsilingiris, D., Eleftheriadou, I., Skouloudi, M., Kanellopoulos, P. N., Lambadiari, V., Masoura, C., et al. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107913 · Cited by 9
Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy
Stelmaszyk, A., Mikołajczak, P. Ł., & Dworacka, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174289 · Cited by 9
Denimal, D., Monier, S., Simoneau, I., Duvillard, L., Vergès, B. L., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01591-9 · Cited by 9
Gómez, P. R. D. V., Mateo‐Rodríguez, C., Vivas-López, C., Olmedo, I. S., Méndez-Muros, M., Morales, C., Jiménez, M. S., Hernández-Herrero, C., & Martínez‐Brocca, M. A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.11.002 · Cited by 9
Singh, K. N., Sandler, S., & Espes, D. (2017) · Journal of Diabetes Research · doi:10.1155/2017/6192896 · Cited by 9
He, J., Xi, Y., Lam, H., Du, K., Chen, D., Dong, Z., & Xiao, J. (2023) · Journal of Diabetes Research · doi:10.1155/2023/8818502 · Cited by 8
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Hamad, M. A. S., Kisters, J. M. H., Timmermans, M. J. C., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02356-2 · Cited by 8
Liarakos, A. L., Crabtree, T. S. J., Griffin, T. P., Hussain, S., Gallen, G., Elliott, J., Furlong, N. J., Narendran, P., Thabit, H., Leelarathna, L., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0165 · Cited by 10
Regional differences in the incidence of diabetic cardiovascular events reflect the quality of care
Winell, K., Arffman, M., Pietilä, A., & Salomaa, V. V. (2018) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2018.1497198 · Cited by 8
Moes, R. G. J., Huisman, E. L., Malkin, S. J. P., & Hunt, B. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s391626 · Cited by 8
Kugathasan, L., Sridhar, V. S., Lytvyn, Y., Lovblom, L. E., Perkins, B. A., Advani, A., & Cherney, D. Z. I. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111764 · Cited by 8
Zhu, J., Xu, J., Yang, C., Gu, Y., Li, J., Zhou, Y., Zhu, M., Hsu, H.-T., Huang, X., Yuan, C., et al. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9070-7 · Cited by 8
Understanding of type 1 diabetes mellitus: what we know and where we go
Cheon, C. K. (2018) · Korean Journal of Pediatrics · doi:10.3345/kjp.2018.06870 · Cited by 9
Diabetes Mellitus Type 1 In Children
LOS, E. A., & Wilt, A. (2019) · StatPearls · Cited by 8
Abiru, N., Shimada, A., Nishimura, R., Matsuhisa, M., Ozaki, A., & Ikegami, H. (2021) · Diabetology International · doi:10.1007/s13340-021-00504-7 · Cited by 9
Matetić, A., Doolub, G., Bharadwaj, A. S., Osman, M., Biondi‐Zoccai, G., Ullah, W., Bagur, R., Velagapudi, P., Alraies, M. C., Mohamed, M., et al. (2021) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2021.08.018 · Cited by 8
Gómez, P. R. D. V., Mateo‐Rodríguez, C., Vivas-López, C., Olmedo, I. S., Méndez-Muros, M., Morales, C., Jiménez, M. S., Hernández-Herrero, C., & Martínez‐Brocca, M. A. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.09.008 · Cited by 8
Toward Personalized Hemoglobin A1c Estimation for Type 2 Diabetes
Kim, N., Lee, D. Y., Seo, W., Kim, N. H., & Park, S. (2022) · IEEE Sensors Journal · doi:10.1109/jsen.2022.3215004 · Cited by 10
Maddaloni, E., Carlone, A., Pitocco, D., Leanza, G., SURACI, C., Altomare, M., Cavallo, M. G., Barchetta, I., Morano, S., Moretti, C., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15213 · Cited by 11
Walker, G. S., Cunningham, S. G., Sainsbury, C. A. R., & Jones, G. C. (2017) · Diabetic Medicine · doi:10.1111/dme.13455 · Cited by 8
Juel, N. G., Brox, J., Hellund, J., Holte, K., & Berg, T. (2017) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2017.1397189 · Cited by 8
Bennett, H., Tank, A., Evans, M., Bergenheim, K., & McEwan, P. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13992 · Cited by 8
Helleputte, S., Backer, T. L. M. D., Calders, P., Pauwels, B., Shadid, S., & Lapauw, B. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0293 · Cited by 8
Schmidt, S., Madsen, K. P., Pedersen-Bjergaard, U., Rytter, K., Hommel, E., Cleal, B., Willaing, I., Andersen, H. U., & Nørgaard, K. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02081-4 · Cited by 5
Watso, J. C., Robinson, A. T., Singar, S., Cuba, J. N., & Koutnik, A. P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00694.2023 · Cited by 8
All-cause mortality and factors associated with it in Finnish patients with type 1 diabetes
Putula, E., Kauppala, T., Vanhamäki, S., Haapakoski, J., Laatikainen, T. K., & Metso, S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108881 · Cited by 12
Obesity, Metabolic Health, and Diabetic Complications in People With Type 1 Diabetes
Mao, Y., Gau, J., & Jiang, N. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70017 · Cited by 7
Wang, S., Zhang, Y., Balati, A., Li, B., Dai, L., & Yu, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf016 · Cited by 6
McAleese, C. A., Joudah, G., Salt, I. P., Petrie, J. R., LEIPER, J. M., & Dowsett, L. (2025) · The Journal of Physiology · doi:10.1113/jp288006 · Cited by 7
DHFR-Driven Metabolic Memory Sustains Periodontal Tissue Destruction
Nie, L., Sun, Y., Dong, H., You, M., Cui, A., Yue, Z., Zhao, P., Lv, Q., Ji, N., Wang, H., et al. (2025) · Journal of Dental Research · doi:10.1177/00220345251340632 · Cited by 7
Steno-2 — a small study with a big heart
BAJAJ, H. S., & Zinman, B. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.172 · Cited by 7
Pothen, L., Verdoy, R., Mulder, D. D., Esfahani, H., Farah, C., Michel, L. Y. M., Zotti, F. D., Bearzatto, B., Ambroise, J., Bouzin, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.854361 · Cited by 7
Chambers, M. A., Hoekstra, F., Radcliffe, I. K., Puffenberger, S. S., Holzmeister, L. A., McClellan, D. R., Shaibi, G. Q., & KAPADIA, C. R. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.015 · Cited by 7
Deshmukh, H., Wilmot, E. G., Pieri, B. A., Choudhary, P., Shah, N. Z., Gregory, R., Kilvert, A., Lumb, A. N., Christian, P., Barnes, D., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14942 · Cited by 7
Zubkiewicz‐Kucharska, A., Wikiera, B., & Noczyńska, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.991269 · Cited by 7
Giannoulaki, P., Kotzakioulafi, E., Nakas, A., Kontoninas, Z., Karlafti, E., Evripidou, P., Kantartzis, K., Savopoulos, C. G., Chourdakis, M., & Didangelos, T. (2024) · Nutrients · doi:10.3390/nu16132089 · Cited by 7
Solà, C., Viñals, C., Serés‐Noriega, T., Perea, V., Esmatjes, E., Boswell, L., Pané, A., Blanco-Carrasco, A. J., Vinagre, I., Mesa, A., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111771 · Cited by 7
Kabadi, U. M. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.113007 · Cited by 7
CVOTs: What did the endocrinologist learn?
Valensi, P. E., & Prévost, G. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107947 · Cited by 6
Tan, J. W. C., Sim, D., Ako, J., Almahmeed, W. A., Cooper, M. E., Dalal, J. J., Deerochanawong, C., Huang, D. W. C., Johar, S., Kaul, U., et al. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.52 · Cited by 8
Perkins, B. A., Bebu, I., Gao, X., Karger, A. B., Hirsch, I. B., Karanchi, H., Molitch, M. E., Zinman, B., Lachin, J. M., & de Boer, I. H. (2022) · Diabetes Care · doi:10.2337/dc21-1883 · Cited by 9
Fedyaeva, V. K., Omelyanovskiy, V. V., Sukhorukikh, O. A., Ryzhov, A. O., & Mochalova, A. A. (2022) · Medical Technologies Assessment and Choice · doi:10.17116/medtech20224401123 · Cited by 7
Notemi, L. M., Amoura, L., Fall-Mostaine, F., Meyer, L., Paris, D., Talha, S., Pottecher, J., & Kessler, L. (2022) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2022.100306 · Cited by 7
Evolution of blood glucose self-monitoring technology
Суплотова, Л. А., & Alieva, O. O. (2023) · Diabetes Mellitus · doi:10.14341/dm13063 · Cited by 7
Alhmoud, E., Saad, M. O., & Omar, N. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1285147 · Cited by 7
Mallone, R., Bismuth, É., Thivolet, C., Benhamou, P., Hoffmeister, N., Collet, F., Nicolino, M. P., Reynaud, R., Beltrand, J., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.06.003 · Cited by 8
The phenomenon of HbA1c stability and the risk of hypoglycemia in long-standing type 1 diabetes
Wolnik, B., Orłowska-Kunikowska, E., Błaszkowska, M., Graff, B., Wolf, J., Czupryniak, L., & Narkiewicz, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.010 · Cited by 7
Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial
Lipska, K. J., & Laiteerapong, N. (2019) · New England Journal of Medicine · doi:10.1056/nejme1905495 · Cited by 7
Khatri, M., Ryan, C. M., Gao, X., de Boer, I. H., Braffett, B. H., Molitch, M. E., Karger, A. B., Lorenzi, G. M., Lee, P., Trapani, V. R., et al. (2023) · Kidney360 · doi:10.34067/kid.0000000000000178 · Cited by 6
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
CHENG, A. Y. Y., Heine, R. J., Prato, S. D., Green, J. B., Thieu, V. T., & Zeytinoglu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16206 · Cited by 6
Jones, T. L. Z., Kusmartseva, I., Litovsky, S. H., Thakar, R. G., Posgai, A. L., Eckel, R. H., & Atkinson, M. A. (2025) · Diabetes · doi:10.2337/db25-0017 · Cited by 8
Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC
Kliemank, E., von Rauchhaupt, E., Seebauer, L., Roshan, M., Ansmann, M., Flegka, V., Schimpfle, L., Tsilingiris, D., Bartl, H., Fleming, T. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15343-8 · Cited by 7
Remnant Cholesterol: From Pathophysiology to Clinical Implications in Type 1 Diabetes
Sebastián‐Valles, F., Muñiz, Á. M., & Marazuela, M. (2025) · Endocrines · doi:10.3390/endocrines6030046 · Cited by 6
Nghiem, T. P., Tran, H. M., Nguyen, D. N. Q., Dao, L. T., Tran, C. C., & Tuan, V. M. (2025) · Medical Sciences · doi:10.3390/medsci13040237 · Cited by 6
Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?
Riveline, J., Hopley, C. D. J., Olivieri, A., Guigand, G., Littlewood, M., & Penfornis, A. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101721 · Cited by 6
Razi, F. B., Ashraf, H., Singhal, S., Qamar, Z., & Moin, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113172 · Cited by 6
Gjorup, A. L. T., Snoek, F. J., & van Duinkerken, E. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.727029 · Cited by 9
Wijk, I., Amsberg, S., Gleissman, S. A., Toft, E., Anderbro, T., & Johansson, U. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01443-z · Cited by 6
Fridolfsson, C., Thegerström, J., Åkesson, K., Engvall, J. E., & Blomstrand, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-54597-6 · Cited by 6
Kaddour, N., Benyettou, F., Moulai, K., Mebarki, A., Taouli, K., Ghemrawi, R., Whelan, J., Merzouk, H., Trabolsi, A., & Mokhtari-Soulimane, N. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30450 · Cited by 7
Narum, M., Seljeflot, I., Bratseth, V., Berg, T. J., & Sveen, K. A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02509-3 · Cited by 6
Role of Devices in Insulin Delivery
Meneghini, L., & McNulty, J. N. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0011 · Cited by 6
Monnier, L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30031-7 · Cited by 6
Takahashi, H., Nishimura, R., Onda, Y., Ando, K., Tsujino, D., & Utsunomiya, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177283 · Cited by 7
Heald, A. H., Livingston, M. A., Fryer, A. A., Cortés, G., Anderson, S. G., Gadsby, R., Laing, I., Lunt, M., Young, R. J., & Stedman, M. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13252 · Cited by 6
Variability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time
Fryer, A. A., Holland, D., Stedman, M., Duff, C. J., Green, L., Scargill, J., Hanna, F., Wu, P., Pemberton, R., Bloor, C., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7093707 · Cited by 6
Case-control Investigation of Previously Undiagnosed Diabetes in the Critically Ill
Krinsley, J. S., Roberts, G., Brownlee, M., Schwartz, M. W., Preiser, J., Rule, P., Wang, Y., Bahgat, J., Umpierrez, G. E., & Hirsch, I. B. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac180 · Cited by 6
Colley, J., Dambha‐Miller, H., Stuart, B. L., Bartholomew, J., Benton, M., Baykoca, J., & Price, H. C. (2022) · Diabetic Medicine · doi:10.1111/dme.15033 · Cited by 7
Shen, Q., He, T., Li, T., Szeto, I. M., Mao, S., Zhong, W., Li, P., Jiang, H., & Zhang, Y. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1156404 · Cited by 7
Neubauer‐Geryk, J., Wielicka, M., Myśliwiec, M., Zorena, K., & Bieniaszewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063190 · Cited by 6
Campbell, M. D., West, D. J., O’Mahoney, L. L., Pearson, S. M., Kietsiriroje, N., Holmes, M. J., & Ajjan, R. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01015-1 · Cited by 6
Effect of Home Enteral Nutrition on Diabetes and Its Management
Vallumsetla, N., Epp, L., Hurt, R. T., & Mundi, M. S. (2018) · Nutrition in Clinical Practice · doi:10.1002/ncp.10104 · Cited by 6
Otani, T., Kasahara, T., Miura, J., Uchigata, Y., & Babazono, T. (2019) · Diabetology International · doi:10.1007/s13340-019-00393-x · Cited by 7
Lachin, J. M., & Nathan, D. M. (2021) · doi:10.2337/figshare.14611245.v1 · Cited by 6
Masouri, M. M., Ebrahimi, R., & Noori, S. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70060 · Cited by 8
Jia, Y., Long, D., Song, W., Wang, Q., & Zhang, Q. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09981-6 · Cited by 5
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 6
Type 1 diabetes in schools: An integrative review of the literature
Parke, S., James, S., Paterson, M. A., King, B. R., & Craft, J. A. (2023) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2023.10.012 · Cited by 5
Metadata
- Authors
- The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
- Corresponding author
- The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-02-09
- Volume
- 39
- Issue
- 5
- Pages
- 686-693
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4839174
- OpenAlex
- W2346630656
- Cited by
- 712
- References
- 39
- Citations by year
- 2026: 60 · 2025: 77 · 2024: 78 · 2023: 63 · 2022: 88 · 2021: 57 · 2020: 67 · 2019: 79 · 2018: 65 · 2017: 56 · 2016: 22
- FWCI
- 74.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Disease
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, tight glycemic control, cardiovascular disease, long-term cardiovascular outcomes, HbA1c, albuminuria, myocardial infarction, stroke, cardiovascular mortality, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Risk Factors, Cohort Studies, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
